Jason C Mixdorf
Overview
Explore the profile of Jason C Mixdorf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang W, Wang T, Chao F, Yang Q, Mixdorf J, Li L, et al.
Mol Pharm
. 2025 Mar;
PMID: 40059341
Trop2 exhibits significantly elevated expression in numerous solid malignancies, playing a crucial role in tumor advancement, whereas its presence in healthy tissues is minimal. In this study, we investigated Trop2...
2.
Li X, Zhang Y, Mixdorf J, Wu Q, Lee S, Engle J, et al.
J Nucl Med
. 2025 Feb;
PMID: 40015924
CD70 is an emerging biomarker for both solid tumors and hematologic malignancies, highlighting the urgent need for a molecular imaging tracer capable of visualizing CD70 with favorable pharmacokinetics. ABDB6 was...
3.
Huang W, Zhang Y, Xiao X, Yang Q, Mixdorf J, Sun X, et al.
Eur J Nucl Med Mol Imaging
. 2025 Feb;
PMID: 39994021
Purpose: The Trop2-targeting antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) has demonstrated remarkable efficacy in patients with metastatic triple-negative breast cancer (TNBC). ImmunoPET imaging offers a noninvasive method to visualize the...
4.
Huang W, Li L, Zhou Y, Yang Q, Mixdorf J, Barnhart T, et al.
Eur J Nucl Med Mol Imaging
. 2025 Jan;
PMID: 39878898
Purpose: Trophoblast cell-surface antigen 2 (Trop2) is overexpressed in various solid tumors and contributes to tumor progression, while its expression remains low in normal tissues. Trop2-targeting antibody-drug conjugate (ADC), sacituzumab...
5.
Gunaratne G, Gallant J, Ott K, Broome P, Celada S, West J, et al.
bioRxiv
. 2025 Jan;
PMID: 39868181
Cancer-associated fibroblasts (CAFs) in the stroma of solid tumors promote an immunosuppressive tumor microenvironment (TME) that drives resistance to therapies. The expression of the protease fibroblast activation protein (FAP) on...
6.
Barrett K, Mixdorf J, Svedjehed J, Batterton J, Eagleburger J, Yan Y, et al.
Nucl Med Biol
. 2024 Dec;
142-143:108989.
PMID: 39729887
We report DGA extraction chromatography isolation of Mn from isotopically enriched Fe. The method has been studied in semi-automated and automated realizations. The former achieves a decay corrected radiochemical yield...
7.
Li X, Song W, Engle J, Mixdorf J, Barnhart T, Sun Y, et al.
Mol Pharm
. 2024 Nov;
21(12):6411-6422.
PMID: 39533706
CD93 is overexpressed in multiple solid tumor types, serving as a novel target for antiangiogenic therapy. The goal of this study was to develop a Cu-based positron emission tomography (PET)...
8.
Olson A, Verich F, Ellison P, Aluicio-Sarduy E, Nickles R, Mixdorf J, et al.
EJNMMI Radiopharm Chem
. 2024 Oct;
9(1):72.
PMID: 39438347
Background: Radiopharmaceutical therapy (RPT) uses radionuclides that decay via one of three therapeutically relevant decay modes (alpha, beta, and internal conversion (IC) / Auger electron (AE) emission) to deliver short...
9.
Kelderman C, Glaser O, Whetter J, Aluicio-Sarduy E, Mixdorf J, Sanders K, et al.
Chem Sci
. 2024 Oct;
PMID: 39397825
The widely established PET isotope F does not have a therapeutic partner. We have recently established that the Sc-F bond can be formed under aqueous, high yielding conditions, paving the...
10.
Lin W, Smilowicz D, Joaqui-Joaqui M, Bera A, Zhong Z, Aluicio-Sarduy E, et al.
Angew Chem Int Ed Engl
. 2024 Sep;
63(50):e202412357.
PMID: 39312186
The elementally matched Co (t=17.53 h, I=77 %)/Co (t=9.10 h, internal conversion=100 %) radioisotope pair is of interest for development of paired diagnostic/therapeutic radiopharmaceuticals. Due to the accessibility of the...